European Patent Office Upholds ARS Patent for Nasal Spray to Treat Allergic Reaction
Dow Jones10-08
By Nicholas G. Miller
The European Patent Office upheld ARS Pharmaceuticals' novel claims in its patent for an epinephrine nasal spray to treat allergic reactions, the company said.
ARS said its global intellectual property related to the nasal spray, called neffy, provides coverage until at least 2039.
Earlier this year, the U.S. Patent and Trademark Office upheld a similar ARS patent following an independent challenge.
Write to Nicholas G. Miller at nicholas.miller@wsj.com
(END) Dow Jones Newswires
October 08, 2025 08:30 ET (12:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments